MET and neoplasm: In preclinical studies, SGX-523 (a selective c-Met inhibitor) [56, 68], crizotinib (an ALK/c-Met/ROS-1 inhibitor) [56, 60, 68], PHA-665752 (a c-Met kinase inhibitor) [69], E7050 (c-Met/VEGFR-2 inhibitor) [70], JNJ-61186372 (an EGFR/Met antibody) [71], tepotinib (a selective c-Met inhibitor) [72], anti-HGF neutralizing antibody, and HGF antagonist NK4 [63] plus new generation EGFR-TKIs can lead to dramatically regression of resistant tumor and delay the occurrence of drug resistance.